SEC Tracker
Get the app
XBIO · XBRL financial data

Xenetic Biosciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (XBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue611672*511726614649*5935901,027766*807661
Research and development1,021976*9449343681,042*879657756773*661552
General and administrative737952*8351,130746706*657658815616*6481,080
Total operating expenses1,7581,928*1,7792,0641,1141,748*1,5361,3141,5721,389*1,3091,632
Operating income (loss)(1,147)(1,256)*(1,268)(1,337)(499)(1,099)*(942)(724)(545)(623)*(502)(972)
Interest income——————3934——4642
Other income (expense)(1)0*0(0)2(7)*0140*(0)(0)
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(1,056)(1,172)*(1,195)(1,274)(437)(1,055)*(903)(689)(510)(579)*(456)(930)
Earnings per share, basic USD per share(0.69)—(0.78)(0.83)(0.28)(0.68)*(0.59)(0.45)(0.33)—(0.20)(0.41)
Earnings per share, diluted USD per share(0.69)—(0.78)(0.83)(0.28)(0.68)*(0.59)(0.45)(0.33)—(0.20)(0.41)
Weighted average shares, basic thousands of shares1,533—1,5411,5411,5421,542*1,5421,5421,542—2,2912,294
Weighted average shares, diluted thousands of shares1,533—1,5411,5411,5421,542*1,5421,5421,542—2,2912,294

Balance sheet

CSV

Fiscal quarters (XBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9,7768,9837,8247,2996,8406,1665,1644,7804,1227,8847,3476,472
Prepaid and other current assets1,481604552716188422314574946166248182
Total current assets11,2579,5878,3768,0157,0286,5885,4775,3545,0688,0507,5956,654
Total assets11,96110,6059,3949,0338,0466,9015,7915,3545,0688,3647,9096,968
Accounts payable449241210284243284240347578258559323
Accrued liabilities—569———611———710——
Total current liabilities1,0688107161,5881,0098946689031,112968958895
Total liabilities1,0688107161,5881,0098946689031,112968958895
Accumulated deficit(192,063)(193,234)(194,429)(195,703)(196,140)(197,194)(198,098)(198,786)(199,296)(199,875)(200,332)(201,261)
Total stockholders' equity10,8939,7968,6787,4467,0376,0075,1234,4503,9567,3966,9516,073
Total liabilities and equity11,96110,6059,3949,0338,0466,9015,7915,3545,0688,3647,9096,968
Common shares outstanding (cover page) thousands of shares1,5411,5411,5411,5421,5421,5421,5421,5422,2912,2912,2912,343

Cash flows

CSV

Fiscal quarters (XBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,056)(1,172)*(1,195)(1,274)(437)(1,055)*(903)(689)(510)(579)*(456)(930)
Stock-based compensation7075*77422825*19161614*1152
Net cash from operating activities(950)*(793)*(1,159)(525)*(459)*(674)*(1,002)(384)*(658)*(243)*(536)(875)*
Net cash from investing activities0*0*——————————
Proceeds from issuing common stock—————year only———year only——
Net cash from financing activities—————year only———year only——

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Xenetic Biosciences6,472661(875)*2.3M7.4 quarters 10-QJun 30, 2026
Skinvisible452.2*5.4M— 10-QJun 30, 2026
Viskase Holdings7,74795,279454*14.3M— 10-QSep 30, 2026
Silo Pharma3,2770*(782)*1.6M6.7 quarters 10-QJun 30, 2026
Astria Therapeutics96,280706(32,295)*57.1M7.1 quarters 10-QSep 30, 2025
Aspira Women's Health47717(2,010)*46.6M0.2 quarters 10-QJun 30, 2026
Adia Nutrition128485(109)*94.4M1.2 quarters 10-QJun 30, 2026
Creative Medical Technology Holdings8,7140(1,472)*6.6M5.9 quarters 10-QJun 30, 2026
Target Group141,381(223)*617.0M0.1 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.